Skip to main content

Table 1 Demographic and clinical characteristics of the patients by group

From: Neurodegeneration in systemic lupus erythematosus: layer by layer retinal study using optical coherence tomography

VariablesSLE group (n = 68)Control group (n = 50)p-value
Age, years45.50 (12.67)52.76 (14.45)0.003
Female sex, n (%)58 (85.3)43 (86)0.914*
Body mass index, kg/m224.64 (3.91)25.79 (3.73)0.070
BCVA, logMAR0.010 (0.051)0.005 (0.020)0.890
IOP-Goldmann, mm Hg13.60 (2.88)13.76 (2.55)0.738
Spherical equivalent, D− 0.25 (− 1.0 to 0.25)0.13 (− 0.63 to 1.0)0.048
Axial length, mm23.56 (1.00)22.89 (0.96)< 0.001
MAP, mm Hg88.71 (11.06)91.92 (13.11)0.114
SLE duration, years11.0 (6.25–19.0)NA 
SLEDAI2 (0–4)NA 
 Daily dose, mg329 (96)NA 
 Cumulative dose, g778 (228.1–1606.0)NA 
 Therapy duration, years5.30 (1.81–11.83)NA 
 Daily dose/weight, mg/kg5.02 (1.61)NA 
 Cumulative dose/weight, g/kg10.76 (3.16–25.47)NA 
NP-SLE, n (%)19 (27.9)NA 
 Central NP-SLE, n (%)16 (23.5)NA 
 Peripheral NP-SLE, n (%)3 (4.4)NA 
Lupus nephritis, n (%)18 (26.5)NA 
Antiphospholipid syndrome, n (%)21 (30.9)NA 
Sjogren’s syndrome, n (%)5 (7.4)NA 
  1. The results are expressed as the mean (SD) or median (P25–P75) for continuous variables or as n (%) for categorical variables
  2. BCVA best corrected visual acuity, HCQ hydroxychloroquine, IOP intraocular pressure, logMAR logarithm of the minimum angle of resolution, MAP mean arterial pressure, NA not applicable, NP-SLE neuropsychiatric systemic lupus erythematosus, SLE systemic lupus erythematosus, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
  3. *Chi-square test; remaining p-values were obtained by the Mann–Whitney test